Reversal of cognitive decline: A novel therapeutic program
http://www.impactaging.com/papers/v6/n9 ... 00690.html
It's very impressive in that cognition was reversed for 9 of the 10 participants. Half of whom were E4 carriers. I've communicated with the author, Dr. Dale Breseden, and received this note from him:
If you are interested in learning more, please let me know ASAP so I can let Dr. Breseden know how many may be interested. I, for one, am jumping at the opportunity. I'm basically already following his protocol. The opportunity to have such close monitoring is invaluable. I encourage everyone to consider.Dear Julie,
> Thanks very much for your note. We have been working toward
> understanding the basic mechanisms of neurodegeneration for 25 years,
> and it is very exciting for me to see patients who are, for the first
> time, actually improving in their cognition, often back to normal,
> and remaining so. We also have new basic research, which should be
> published over the next few months, that identifies a completely
> novel mechanism by which ApoE4 confers risk for Alzheimer's and other
> chronic illnesses.
>
> Meanwhile, I wonder whether it may be of interest to include your
> entire group in a study, in which the goal would be to reverse the
> cognitive decline for those who have started it and prevent cognitive
> decline for those who are currently presymptomatic. As I mentioned
> in the paper, just over half of the initial patients are ApoE4
> positive (and additional ones not in this first paper).
>
> Do you think the group (or a subset thereof) would be interested in
> going through the whole protocol? Also, do you have a sense of how
> many are symptomatic vs. asymptomatic/presymptomatic? If there is
> significant interest, it may be of great interest--and hopefully
> great effect--to get a significant fraction of the members into the
> protocol, starting with identifying the key driving parameters for
> each person, and then putting together a personalized program for
> each.
>
> If you think there may be interest in this, please let me know.
>
> Best regards,
> Dale
> ____________________________________________________
> Dale E. Bredesen, M.D.
> Augustus Rose Professor of Neurology
> Director, Mary S. Easton Center for
> Alzheimer’s Disease Research at UCLA
> Director, Alzheimer’s Disease Program
> Director, Neurodegenerative Disease Research
> David Geffen School of Medicine at UCLA
> Founding President, Buck Institute
> ________________________________________